NanoViricides, Inc. develops antiviral therapeutics using its proprietary nanoviricide technology, which targets a wide range of viruses. The company is focused on creating broad-spectrum nanoviricides for various viral diseases, including respiratory syncytial virus (RSV), COVID-19, influenza, and Ebola. Its product pipeline includes NV-387, which is in clinical trials for treating Ebola and other viral infections. NanoViricides operates primarily in the pharmaceutical sector, targeting healthcare providers and patients globally, with ongoing clinical trials in regions affected by viral outbreaks.
- Website
- www.nanoviricides.com
- Issuer profile
- All listings